# Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis

> **NCT06886009** · — · WITHDRAWN · sponsor: **Boehringer Ingelheim**

## Conditions studied

- Generalized Pustular Psoriasis

## Interventions

- **DRUG:** Spevigo®

## Key facts

- **NCT ID:** NCT06886009
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-03-31
- **Primary completion:** 2029-06-08
- **Final completion:** 2029-06-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06886009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06886009, "Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06886009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*